Skip to main content

Table 1 Baseline characteristics

From: 4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry

Variable

Value

Total no patients

403

Age

 Mean (SD)

47 (15.6)

Gender (%)

 Male

149 (37.0)

 Female

253 (62.8)

Body weight, kg

 Mean (SD)

78.6 (17.4)

Baseline IgE level, IU/mL

 Mean (SD)

619. 9 (1036.4)

 Range

3–10,800

Severe allergic asthma (%)

 Yes

380 (94.3)

 No

12 (3.0)

Positive skin-prick test/RAST (%)

 Yes

363 (90.3)

 No

26 (6.5)

FEV1 <80 (%)

 Yes

279 (69.2)

 No

116 (28.8)

More than 2 exacerbations (%)

 Yes

384 (95.3)

 No

11 (2.7)

Maximum dose ICS and LABAs (%)

 Yes

394 (99)

 No

4 (1)

Smoking (%)

 Tried to quit smoking

101 (25.1)

 Didn’t try to quit smoking

29 (7.2)